Supplementary Data 1 from A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
Won Seog Kim,Jake Shortt,Pier Luigi Zinzani, Natalia Mikhailova, Dejan Radeski, Vincent Ribrag, Eva Domingo Domenech,Ahmed Sawas, Karenza Alexis, Michael Emig, Riham Elbadri, Pallavi Hajela,Paulien Ravenstijn, Sheena Pinto, Linta Garcia,Andre Overesch, Kerstin Pietzko,Steven Horwitz crossref（2025）
AI 理解论文
溯源树
样例
